At Immunostep we have been innovating since 2001 to develop comprehensive products related to Flow Cytometry that contribute to improve performance in key areas of clinical Research and Diagnostic development. Our goal is to improve performance by innovating and adapting new technology to collaborate building meaningful clinical investigation.
At the leading-edge of technology in research areas of development
As a leading provider of technologies, tools, and services for bioscience and biopharmaceutical manufacturing, we offer a wide range of assays, kits and solutions for Flow Cytometry.
In 2017 Immunostep R&D team recognized the great potential of exosomes and since then we have been working on the development of a method for detecting, isolating and quantifying extracellular vesicles which are present in fluid samples.
As a response to SARs-CoV-2 global emergency we developed a product line in order to improve serological testing performance and help building clinical investigation around Covid-19 disease.
We find the most innovative technology and use them to build adaptative clinical products to diagnose and treat diseases, and we work to achieve our goals under a strict system of values:
We seek always to be at the leading-edge of technology in research areas of development, and in order to achieve that goal, we work under an extensive R&D program headed by a brilliant team of Flow Cytometry experts.
Immunostep strongly supports the renewal of investment in science and technology to support the development of the scientific community and its research efforts on a global scale.
Intensifying our commitment to offer high quality products, Immunostep works under an ISO 13485: 2018 Certified Quality Management System, which complies with international standards for the manufacture of medical devices and reagents.
The social well-being of our employees, suppliers and local communities is among our objectives as a socially responsible company. We assess the environmental and social impact of all the projects in which we invest and collaborate with our customers to reach international best practice agreements.
Contact
For any information required, please use the form below and we will contact you shortly.